Redesigned Pre-Submission Meetings in GDUFA III: Benefits for ANDA Submission and Approval - 05/09/2024
On May 9, 2024, the FDA’s Office of Generic Drugs hosted a webinar on the redesigned pre‑submission meetings under GDUFA III. The session outlined new scope, procedural updates, and illustrated a hypothetical case to help sponsors prepare effective meeting requests. Speakers included senior regulators from OGD, ORS, and OPQ, followed by a panel discussion and live Q&A. Attendees received links to the latest GDUFA III guidance and performance‑goal documents.
AI Can Streamline Drug Approval, Boost Biotech Valuations
That is an interesting idea. This doesn't seem catered to investors per se, but with two partners in the summer of 25, we explored building an “AI-powered AlphaSense for biopharma” ultimately concluding it was too much work to do as...
Complex Generics News
The FDA’s Center for Drug Evaluation and Research is intensifying its focus on complex generic drugs, which feature intricate active ingredients, formulations, or delivery systems. Recent milestones include the July 2023 approval of the first generic Vivitrol injectable and the March 2026...
Genflow and Acuitas Forge Fully Funded LNP Collaboration to Accelerate SIRT6 Gene Therapies
Genflow Biosciences announced a strategic, fully funded collaboration with Acuitas Therapeutics to apply Acuitas' lipid‑nanoparticle (LNP) delivery platform to Genflow's SIRT6 mRNA payload. The non‑dilutive agreement lets Genflow generate preclinical data without cash outlay, signaling strong external validation of its...
From Dorm to $275M: Early Ovarian Cancer Detection Breakthrough
This is my friend Surbhi Sarna. She came to Draper University in 2012. She had painful ovarian cysts as a teenager, but doctors didn’t have tools that could detect cancer without harming the ovaries. She studied molecular biology at UC Berkeley. Then came...
Xenon’s Azetukalner Clears Phase III Hurdle in Focal Epilepsy, Eyes FDA Filing
Xenon Pharmaceuticals reported on 19 April at the American Academy of Neurology that its KV7 potassium‑channel opener azetukalner met primary endpoints in the Phase III X‑TOLE2 trial for focal onset seizures. The study enrolled 380 adults, with 374 completing safety and...
Architecting Life: Authoring the Future of Species with Dr. Adrian Woolfson
Dr. Adrian Woolfson argues that DNA must be treated as a programmable engineering material, enabling the design of living systems from houses to organs. By decoding DNA's generative grammar, humanity could author genomes and potentially rewrite its own code, ushering...
'It's Just the Beginning' For Pancreatic Cancer's Long-Awaited Breakthrough
Revolution Medicines’ KRAS‑G12D inhibitor daraxonrasib has entered late‑stage trials as a potential first‑in‑class therapy for pancreatic cancer, a disease that still carries a five‑year survival rate below 12%. Early data show tumor shrinkage in roughly a third of heavily pre‑treated...
SMMT Spikes as Akeso OS Data Lands Plenary
Summit Thera. $SMMT Well… that answers that. SMMT shares initially popped (as much as ~15%) on today’s release of ASCO abstract titles with the unexpected news that the much-anticipated OS data from Akeso’s HARMONi-6 will be released in a Plenary slot...
Carvykti Shows Promise Before Multiple Myeloma; Two Megarounds; AstraZeneca Wins Twice
Researchers at Dana‑Farber Cancer Institute reported that all 20 high‑risk smoldering multiple myeloma patients treated with Carvykti, Janssen's BCMA‑directed CAR‑T therapy, achieved disease clearance. The single‑infusion regimen produced complete responses without immediate relapse, and patients remained progression‑free at a median...
BioAge Says Early Data Suggest ‘Best-in-Class’ Potential for Inflammation Drug
BioAge Labs released Phase 1 data for the 60‑mg dose of its NLRP3 inhibitor BGE‑102, confirming tolerability and inflammation‑lowering activity similar to the earlier 120‑mg readout. The oral pill crosses the blood‑brain barrier, opening possibilities for cardiovascular, obesity, eye and central‑nervous‑system...
Early Myocarditis Onset After Immunotherapy May Predict Treatment-Related Fatality
A new analysis of WHO VigiBase data presented at the AACR 2026 meeting shows that immune checkpoint inhibitor (ICI)‑induced myocarditis occurring within the first month of therapy dramatically increases the risk of death. Patients who develop myocarditis early are 59%...
Intralesional Nivolumab May Be Effective Against Precancerous Oral Lesions, Phase I Trial Results Indicate
A Phase I trial presented at AACR 2026 showed that injecting low‑dose nivolumab directly into precancerous oral lesions produced an 85% clinical response rate, with lesions shrinking an average of 60% and 41% achieving histologic downgrading. Patients received 10 mg or 20 mg...
One-Step Method Reveals Structures of RNA-Protein Complexes in Living Cells
Researchers at Baylor College of Medicine introduced a one‑step biochemical technique called multi‑site DMS‑MaP (msDMS‑MaP) that maps RNA three‑dimensional structures and protein‑binding sites directly in living cells. The method simplifies RNA structure probing, uses inexpensive reagents, and integrates with high‑throughput...
Unexpected Cancer Mutations in Brain's Immune Cells May Help Fuel Alzheimer's Disease
Researchers at Boston Children’s Hospital sequenced 149 cancer‑driving genes in 190 Alzheimer’s brains and found microglia accumulating mutations in five oncogenic genes. The same mutations were present in the patients’ blood cells, implying that mutated immune cells cross a weakened...
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
Agenus appointed BAP Pharma as its exclusive global partner to manage early‑access programs for the botensilimab‑balstilimab (BOT+BAL) immunotherapy combo. The collaboration will handle France’s government‑reimbursed Autorisation d’Accès Compassionnel (AAC) pathway and paid named‑patient programs in several other markets. Agenus has...
Charles River Highlights Effectiveness of VCGs in Toxicology
Charles River Laboratories published a retrospective analysis of 20 nonclinical toxicology studies that replaced traditional concurrent control groups with virtual control groups (VCGs). The review found 100% concordance in No Observed Adverse Effect Level (NOAEL) determinations and demonstrated up to...
Star Therapeutics Receives FDA Rare Pediatric Disease and Breakthrough Therapy Designations for VGA039 in Von Willebrand Disease Prophylaxis
Star Therapeutics announced that the FDA has granted both rare pediatric disease and Breakthrough Therapy designations to its lead candidate VGA039, a monoclonal antibody aimed at preventing bleeding in von Willebrand disease (VWD). The designations support the ongoing Phase 3 VIVID‑6 study,...
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products
Simulations Plus announced a funded collaboration with CDMO Lonza and the U.S. FDA to create a mechanistic, predictive framework for amorphous solid dispersion (ASD) oral drugs. The partnership will combine Lonza's advanced in‑vitro dissolution testing with Simulations Plus' GastroPlus and...
HIV's Earliest Immune Battle Leaves Blood Traces that Forecast Powerful Antibodies Years Later
Researchers analyzed cell‑free RNA and DNA from blood samples of 14 South African women tracked from pre‑infection through early HIV infection. They discovered that individuals who later produced broadly neutralizing antibodies (bNAbs) exhibited distinct early immune activation patterns and unique...
Tortugas Takes Neuro Deep Dive with $106M to Develop Eisai, Hansoh Programs
Tortugas, a Massachusetts‑based biotech, launched with $106 million in seed and Series A funding, securing clinical assets from Japan’s Eisai and China’s Hansoh Pharmaceutical. The capital will support two mid‑stage, oral small‑molecule trials targeting CNS disorders such as schizophrenia, tinnitus, and focal...
NIMBLE Trial Shows Efficacy of Cemdisiran in gMG: Tuan Vu, MD
The phase 3 NIMBLE trial evaluated cemdisiran, an RNA‑interference therapy, in patients with generalized myasthenia gravis (gMG). Over 26 weeks, cemdisiran monotherapy and its combination with pozelimab both achieved statistically significant improvements on the MG‑ADL scale versus placebo, and met the key...
Boehringer Targets AI-Driven Advances in Disease Research
Boehringer Ingelheim announced a £150 million (US$203 million) AI and machine‑learning accelerator in King’s Cross, London, expanding its global computational R&D network. The new hub, part of the UK Knowledge Quarter, will focus on disease biology, target identification and predictive modeling to...
Red Wolf Controversy Deepens After Colossal’s Clone Claim
The red wolf has long been a contentious species. The debate over its preservation got even messier last year, when Colossal said it had cloned the animal.
ASCO26 Unveils Pancreatic
#ASCO26 abstract titles were released today: $RVMD RASolute Ph3 study in pancreatic cancer will be presented during the plenary session. Also, Akeso $SMMT ivonescimab HARMONi-6 trial in lung cancer. China-only data.
BioAge Reports Positive Phase 1 Data for BGE-102
BioAge Labs announced Phase 1 results for BGE‑102, an oral, brain‑penetrant NLRP3 inhibitor, showing up to 86% reductions in high‑sensitivity C‑reactive protein (hsCRP) in obese participants. A 60 mg once‑daily regimen over 21 days achieved biomarker improvements comparable to the previously tested...
BioAge's Inflammation Drug Shows Best‑in‑class Promise
BioAge says early data suggest ‘best-in-class’ potential for inflammation drug https://t.co/D2owlYxCRa by Kristin Jensen $BIOA $LLY $NMRA
Nabla Bio Secures Seed Funding Directly at Conference
Some companies raise a seed round. Nabla Bio had one built at a conference. https://t.co/1xmbmuqA8p
![[Comment] Is Partial Complement Blockade Enough in Myasthenia Gravis?](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/efeb4e97504f7f1cdd947972b3a5f013.webp)
[Comment] Is Partial Complement Blockade Enough in Myasthenia Gravis?
The past eight years have seen a rapid expansion of targeted therapies for generalized myasthenia gravis, including complement C5 inhibitors, neonatal Fc receptor antagonists, and the anti‑CD19 B‑cell‑depleting antibody inebilizumab. Clinical trials have demonstrated meaningful reductions in disease activity, prompting...
MRNA Brand Stigmatized by COVID Vaccine Backlash, Says Bhattacharya
That is literally a lie, as Bhattacharya wrote an op-ed trying to explain their move. He essentially was arguing that the "brand" of mRNA is tainted by public backlash to the COVID vaccine. https://t.co/5KXQJtCCxM https://t.co/HDQRvQK0ki
Promising Mufemilast Results Unveiled at DDW
Strong mufemilast data being presented at DDW this week for anyone still following the $PALI story. https://t.co/Oi4WI6R0iW
Clean Food Group Raises £4.5M to Bring “World’s Largest” Yeast-Oil Facility to Full Capacity
Clean Food Group (CFG) raised £4.5 million (≈$5.6 million) in a round led by Clean Growth Fund and New Agrarian, plus a £700,000 (≈$875,000) Innovate UK grant, to finish scaling its 1‑million‑litre fermentation site in Knowsley, Liverpool. The plant, billed as the world’s...
AI Accelerates Small Molecule Synthesis, Says Martin Burke
Small molecule synthesis made faster for the AI era: Listen to Martin Burke on The Long Run. Sponsors: @AlphaSenseInc and Dash Bio. https://t.co/D990phgzg8
Re: Alzheimer’s Drugs Targeting Amyloid Do Not Produce Clinically Meaningful Effects, Concludes Cochrane Review
A recent Cochrane review concluded that amyloid‑targeting drugs for Alzheimer’s disease do not deliver clinically meaningful benefits, prompting disappointment among researchers, investors, and caregivers. In a BMJ rapid response, emeritus professors Elaine and Robert Perry argue that cholinergic therapy—available for...
Merck, Eisai’s Keytruda Triplet Fails to Improve Survival in Kidney Cancer
Merck and Eisai announced that their Phase 3 LITESPARK‑012 trial of a three‑drug regimen—Keytruda, Welireg and Lenvima—failed to improve overall survival or progression‑free survival in first‑line renal cell carcinoma. The control arm received the approved Keytruda‑Lenvima doublet, which also did not...
SaNOtize - 727784 - 04/17/2026
The U.S. Food and Drug Administration issued a warning letter to SaNOtize, the maker of “NOWONDER™ Nasal Cleanser,” on April 17, 2026. The agency determined the product is an unapproved new drug because its labeling and website claim nitric‑oxide‑based immune benefits, violating sections 505(a)...
Pro Numb Tattoo Numbing Spray, LLC - 722589 - 04/14/2026
The FDA issued a warning letter to Pro Numb Tattoo Numbing Spray, LLC for multiple Current Good Manufacturing Practice (CGMP) violations, including failure to test finished drug batches, inadequate raw‑material verification, and lack of stability data. The firm also marketed...
Mabwell’s T‑mab Subsidiary Clears First‑Time GMP Inspection in Jordan, Boosting Middle‑East Push
Mabwell announced that its subsidiary T‑mab successfully passed a Jordan Food and Drug Administration on‑site GMP inspection, earning a “Compliance” rating for its denosumab biosimilars. The milestone, the company’s first approval from a PIC/S member country, is expected to accelerate...
Eli Lilly to Acquire Kelonia Therapeutics in $7 B Cash Deal
Eli Lilly agreed to acquire Cambridge‑based Kelonia Therapeutics for up to $7 billion in cash, including an undisclosed upfront payment. The deal adds Kelonia’s in‑vivo gene‑delivery platform and its lead candidate KLN‑1010 to Lilly’s oncology portfolio, and sent Lilly’s shares up 2.5%...
Biological Data Is Messy: Human Error Is Inevitable
1/ Biological data isn’t just messy. Humans generate it. And humans make mistakes. As a bioinformatician, this will be your reality 🧵 https://t.co/hjSOBVJvjM
Chinese Researchers Propose Saliva Test to Detect Stomach Cancer Early
Researchers from Shanghai Jiao Tong University School of Medicine have pinpointed 20 bacterial species that appear in both the mouths and stomachs of gastric‑cancer patients. Their study, published in Cell Reports Medicine, proposes a non‑invasive saliva test that could identify...
Scientists Load Complete Hepatitis‑D Genome Onto IBM’s 156‑Qubit Quantum Processor
Teams from the Wellcome Sanger Institute, Oxford, Cambridge and Melbourne have encoded the entire 1,700‑base‑pair hepatitis‑D virus genome onto IBM’s 156‑qubit Heron quantum processor. The proof‑of‑concept demonstrates a pathway to quantum‑accelerated genomics, with researchers eyeing future speedups of up to...
From PhD to Staff Data Scientist in Biotech
Jordan works as a Staff Data Scientist at Recursion in Fort Collins, where he integrates computational workflows with experimental biology to accelerate drug discovery. His daily duties include building high‑dimensional analysis pipelines, collaborating with biologists on experiment design, and presenting...
BBOT Secures FDA Fast Track for Pan-KRAS Inhibitor BBO-11818 in KRAS‑Mutant Pancreatic Cancer
BridgeBio Oncology Therapeutics (BBOT) announced that the FDA granted Fast Track designation to its pan‑KRAS inhibitor BBO-11818 for advanced KRAS‑mutant pancreatic ductal adenocarcinoma. The designation accelerates development of a drug that showed a confirmed partial response in early data and...
Neolaia Synthesizes New CD38 Inhibitors
Biohaven disclosed detailed preclinical data on BHV‑2100, a TRPM3 calcium‑channel modulator aimed at neuropathic pain. A new meta‑analysis concluded that anti‑amyloid therapies for Alzheimer’s have not demonstrated clinically meaningful benefits, intensifying debate over the approach. Jiangsu and Shanghai Hengrui patented...
What New Atopic Dermatitis Treatments Are in the Pipeline in 2026?
The atopic dermatitis pipeline in 2026 is dominated by next‑generation biologics and selective small molecules that aim to improve efficacy while reducing side‑effects. Connect Biopharma’s rademikibart achieved near‑complete skin clearance in a phase 3 trial, and Apogee’s extended‑half‑life zumilokibart showed durable...
Incyte Discloses New TYK2 And/Or JAK1 Inhibitors
Incyte announced the discovery of a new series of small‑molecule inhibitors that selectively target TYK2 and JAK1, two kinases central to cytokine signaling in autoimmune disorders. The compounds demonstrated sub‑nanomolar potency in cell‑based assays and favorable safety margins in early...
The AI Drug Discovery Capital Stack in 2026: Who Has Raised the Most, Why Their Technical Approaches Actually Differ, and...
The essay maps AI‑driven drug‑discovery firms’ capital stacks as of April 2026, highlighting that Eikon, Xaira, Isomorphic Labs and Recursion sit at the top of disclosed funding. It separates the sector into four technical lanes—structure foundation models, generative chemistry, phenomics/perturbational biology,...
Regulatory Hurdles, Not Tech, Slow Biotech Breakthroughs
"We need 6 'AlphaFold' moments to compress the drug delivery timeline from 10yrs to a few months" -Demis Yes and the FDA will still take 10yrs to approve it. Safetyism has throttled biotech unnecessarily and the only way to accelerate is to...
Biocon Receives Health Canada Approval for Bosaya and Vevzuo (Biosimilars, Prolia and Xgeva)
Biocon has secured a Notice of Compliance from Health Canada for its denosumab biosimilars, Bosaya and Vevzuo, which mirror Amgen’s Prolia and Xgeva. The approval follows a comprehensive data package demonstrating comparable quality, safety and efficacy to the reference products....